Risk of cardiac dysfunction in patients receiving anthracyclines across breast cancer and hematologic malignancies: a single-center retrospective cohort study in Japan

Key Points

• Cardiac dysfunction risk is substantial among patients receiving anthracyclines for breast cancer and hematologic malignancies.
• Approximately 30% of those treated showed signs of cardiac dysfunction over a follow-up period of five years.
• Retrospective cohort study analyzed patient records at a single center, focusing on anthracycline treatment outcomes.
• Findings highlight the need for regular cardiac monitoring in patients on anthracyclines to mitigate risks.